Medical
FDA Grants Breakthrough Status to AbbVie Cancer Drug for Two Tumours
The FDA granted two Breakthrough Therapy Designations to AbbVie's telisotuzumab adizutecan for colorectal and lung cancers on October…
The FDA granted two Breakthrough Therapy Designations to AbbVie's telisotuzumab adizutecan for colorectal and lung cancers on October…